ZLDDG
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Zelira Therapeutics Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
5
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Zelira Therapeutics Limited
π Performance
Price History
+209900.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$2.10
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in ZLDDG
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in ZLDDG
N/A
ZLDDG investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in ZLDDG also invest in...
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. The company has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
π Performance (5Yr p.a)
-18.88%
π Share price
$0.49 AUD
π¦ LOGISTICS
Qantas Airways Ltd. engages in international and domestic air transportation services. The company is headquartered in Mascot, New South Wales. The principal activities of the Company include the operation of international and domestic air transportation services and provision of freight services and the operation of a frequent flyer loyalty program. The Companyβs segments include Qantas Domestic, Qantas International, Jetstar Group, Qantas Loyalty, and Corporate. Qantas Domestic is a carrier in the Australian domestic market measured by capacity. Qantas Domestic offers on-board Wi-Fi and upgrades to the domestic lounges. Qantas International is a carrier into and out of Australia, also targeting business and premium leisure customers who value the full-service experience. Jetstar Group has domestic and international routes in Australia, joint ventures in Singapore and Japan. Qantas Loyalty is comprised of consumer and SME coalition loyalty programs. Its airline brands operate regional, domestic, and international services.
π Performance (5Yr p.a)
9.87%
π Share price
$8.99 AUD
π HIGH PRICE GROWTH
βοΈ AIRLINES
IFRA.AX was created on 2016-04-29 by VanEck. The fund's investment portfolio concentrates primarily on theme equity. Each Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars. A Fund does not aim to perfectly replicate its Reference Index on a one-to-one basis
π Performance (5Yr p.a)
-1.07%
π Share price
$21.90 AUD
π GLOBAL
π³ ENVIRONMENTAL
π UTILITIES
π INDUSTRIALS
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
π Performance (5Yr p.a)
11.47%
π Share price
$88.44 AUD
π GLOBAL
ποΈ CONSUMER
π HIGH PRICE GROWTH
π INDUSTRIALS
VGE.AX was created on 2013-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Seeks to track the return of the FTSE Emerging Markets All Cap China A Inclusion Index in Australian dollars, before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
2.49%
π Share price
$81.04 AUD
β³οΈ DIVERSIFIED
π GLOBAL
Want more shares? Try these...
Zinc of Ireland NL engages in the mineral exploration and project evaluation. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2007-09-18. Its 100%-owned Kildare Project is located approximately 40 kilometers (km) southwest of Dublin and comprises approximately 240 square kilometers (km2) of contiguous prospecting licenses. The Earaheedy license is located approximately 200 km east of Wiluna and 220 km southeast of the RTR Chinook and Magazine Pb-Zn discoveries. The Earaheedy license contains approximately 23 km of strike of the target unconformity between the Frere and Yelma formations. The firm also covers approximately 1380 km2 lithium exploration project in the Superior Province, Manitoba, Canada. Through its subsidiary Avignon Resources Pty Ltd, it has six mineral exploration licenses and seven mining claims in Manitoba.
π Performance (5Yr p.a)
-16.72%
π Share price
$0.01 AUD
βοΈ MINING